Literature DB >> 18586274

Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project.

Johannes M Hennings1, Toshimi Owashi, Elisabeth B Binder, Sonja Horstmann, Andreas Menke, Stefan Kloiber, Tatjana Dose, Bastian Wollweber, Derek Spieler, Thomas Messer, Rita Lutz, Heike Künzel, Thomas Bierner, Thomas Pollmächer, Hildegard Pfister, Thomas Nickel, Annette Sonntag, Manfred Uhr, Marcus Ising, Florian Holsboer, Susanne Lucae.   

Abstract

Depression is a common and often difficult-to-treat clinical condition with a high rate of patients showing insufficient treatment response and persistence of symptoms. We report the characteristics of a representative sample of depressed inpatients participating in the Munich Antidepressant Response Signature (MARS) project. Eight hundred and forty-two inpatients admitted to a psychiatric hospital for treatment of a major depressive episode, recurrent or bipolar depression were thoroughly characterized with respect to demographic factors, clinical history, and the degree of HPA-axis dysregulation evaluated by means of combined dex/CRH tests, and the predictive value of these factors for treatment outcome is investigated. 80.8% of patients responded to treatment (i.e., improvement in symptom severity of at least 50%) and 57.9% reached remission (i.e., near absence of residual depressive symptoms) at discharge after a mean treatment period of 11.8 weeks. Regression analysis identified early partial response (within 2 weeks) as the most important positive predictor for achieving remission. Previous ineffective treatment trials in the current episode and presence of a migration background are potent negative predictors for treatment outcome. In addition, remitters were characterized by a more pronounced normalization of an initially dysregulated HPA-axis. We could show that a large majority of inpatients suffering from depression benefits from antidepressant treatment during hospitalization. However, a considerable number of patients failed to achieve remission. We demonstrated that this subgroup can be characterized by a set of demographic, clinical and neuroendocrine variables allowing to predict unfavorable outcome at an early stage of treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586274     DOI: 10.1016/j.jpsychires.2008.05.002

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  61 in total

1.  Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology.

Authors:  Claudia Ditzen; Ning Tang; Archana M Jastorff; Larysa Teplytska; Alexander Yassouridis; Giuseppina Maccarrone; Manfred Uhr; Thomas Bronisch; Christine A Miller; Florian Holsboer; Christoph W Turck
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

2.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

3.  [The German research network for mental disorders].

Authors:  M Bauer; T Banaschewski; A Heinz; I Kamp-Becker; A Meyer-Lindenberg; F Padberg; M A Rapp; R Rupprecht; F Schneider; T G Schulze; H-U Wittchen
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

Review 4.  Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.

Authors:  Eleanor Murphy; Francis J McMahon
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

Review 5.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

Review 6.  Biological basis of depression in adults with diabetes.

Authors:  Shivam Champaneri; Gary S Wand; Saurabh S Malhotra; Sarah S Casagrande; Sherita Hill Golden
Journal:  Curr Diab Rep       Date:  2010-12       Impact factor: 4.810

Review 7.  Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.

Authors:  Benji T Kurian; Tracy L Greer; Madhukar H Trivedi
Journal:  Expert Rev Neurother       Date:  2009-07       Impact factor: 4.618

Review 8.  Suicidal ideation during antidepressant treatment: do genetic predictors exist?

Authors:  Nader Perroud
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

9.  FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications.

Authors:  N C Gassen; J Hartmann; A S Zannas; A Kretzschmar; J Zschocke; G Maccarrone; K Hafner; A Zellner; L K Kollmannsberger; K V Wagner; D Mehta; S Kloiber; C W Turck; S Lucae; G P Chrousos; F Holsboer; E B Binder; M Ising; M V Schmidt; T Rein
Journal:  Mol Psychiatry       Date:  2015-04-07       Impact factor: 15.992

10.  The effectiveness of prefrontal theta cordance and early reduction of depressive symptoms in the prediction of antidepressant treatment outcome in patients with resistant depression: analysis of naturalistic data.

Authors:  Martin Bares; Tomas Novak; Miloslav Kopecek; Martin Brunovsky; Pavla Stopkova; Cyril Höschl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-05-22       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.